**Research Artícle** 

# World Journal of Pharmaceutical and Life Sciences WJPLS

www.wjpls.org

SJIF Impact Factor: 7.409

# *IN-VITRO* EVALUATION OF CELL VIABILITY STUDIES OF OROPHARYNGEAL CANCER USING SIMILAR MOLECULE – LAMBROLIZUMAB

Dr. Syed Ahmed Hussain<sup>\*1</sup>, Umaima Batool Osmani<sup>1</sup>, Raheem Unnisa Shaik<sup>1</sup>, Maimuna Fatima, Arshiya Tarannum<sup>1</sup>, Faheem Unnisa<sup>1</sup> and Nazneen<sup>1</sup>

<sup>1</sup>Department of Pharmacology, Shadan Women's College of Pharmacy, Hyderabad.



\*Corresponding Author: Dr. Syed Ahmed Hussain

Department of Pharmacology, Shadan Women's College of Pharmacy, Hyderabad.

Article Received on 05/09/2024

Article Revised on 26/09/2024

Article Accepted on 16/10/2024

# ABSTRACT

Aim: To evaluate the in vitro cytotoxic effects of Lambrolizumab, a PD-1 inhibitor, in comparison to Cetuximab, a marketed drug, using various cell viability assays. **Objective:** The primary objective of this study is to determine the cytotoxic potential of Lambrolizumab on kidney cancer cell lines and assess its viability as a treatment option for oropharyngeal cancer. **Research:** Five different assays—MTT, CellTiter-Glo Luminescent, Alamar Blue, SRB, and LDH Cytotoxicity—were used to assess cell viability, proliferation, and cytotoxicity. Lambrolizumab demonstrated a significant reduction in cell viability in a dose-dependent manner across all assays, with maximum efficacy at 10  $\mu$ M concentration. Compared to Cetuximab, which maintained 100% cell viability, Lambrolizumab showed enhanced cytotoxic activity, reducing cell viability by up to 42.8% (MTT Assay) and inducing up to 77.2% cell death (LDH Assay). **Conclusion:** The findings suggest that Lambrolizumab possesses a strong cytotoxic profile, making it a promising candidate for further development in oropharyngeal cancer treatment. The study highlights the potential of immune checkpoint inhibitors like Lambrolizumab to provide better therapeutic outcomes in resistant cancer types.

**KEYWORDS:** Lambrolizumab, oropharyngeal cancer, cytotoxicity.

# INTRODUCTION

Oropharyngeal cancer, a subtype of head and neck squamous cell carcinoma (HNSCC), has posed significant therapeutic challenges due to its complex etiology and poor response to conventional treatments. Immune checkpoint inhibitors have emerged as promising therapeutic agents in cancer treatment, offering improved clinical outcomes by modulating the immune system's response to tumor cells. Lambrolizumab, a PD-1 inhibitor, has been evaluated for its efficacy in treating recurrent or metastatic HNSCC. This study focuses on comparing the in vitro cytotoxic effects of Lambrolizumab with a marketed drug, Cetuximab (Erbitux), using a variety of cell viability assays. The results provide valuable insights into the potential therapeutic application of Lambrolizumab in oropharyngeal cancer.

# METHODOLOGY

Oropharyngeal cancer cell lines (e.g., SCC-25, FaDu) Similar molecules of interest (e.g., natural compounds, synthetic compounds)Dulbecco's Modified Eagle Medium (DMEM) or Roswell Park Memorial Institute (RPMI) Medium Fetal bovine serum (FBS) PenicillinStreptomycin solutionTrypsin-EDTA solution Phosphatebuffered saline (PBS)96-well cell culture platesDimethyl sulfoxide (DMSO) Cell viability assay kit (e.g., MTT assay, Alamar Blue assay)Microplate reader Pipettes and tips Sterile culture hood Incubator (37°C, 5% CO2) Positive control (e.g., doxorubicin)Negative control (e.g., DMSO)

## Procedure

Cell Culture: Thaw frozen oropharyngeal cancer cell lines according to standard protocols. Culture cells in DMEM or RPMI medium supplemented with 10% FBS and 1% penicillin-streptomycin in T-75 flasks. Incubate cells at 37°C in a humidified atmosphere with 5% CO2. Passage cells when reaching 70-80% confluency using trypsin-EDTA. Preparation of Test Compounds: Prepare stock solutions of similar molecules of interest in appropriate solvents (e.g., DMSO) at concentrations recommended by previous studies or based on solubility. Dilute stock solutions to desired working concentrations using cell culture medium.

#### **Experimental Setup**

Seed oropharyngeal cancer cells in 96-well plates at a density of 5,000-10,000 cells per well in 100  $\mu$ L of complete growth medium. Allow cells to adhere overnight at 37°C in a CO2 incubator.

# Treatment

Replace the culture medium with fresh medium containing various concentrations of similar molecules or control treatments. Include positive controls (e.g., doxorubicin) and negative controls (e.g., DMSO) in each experiment.

#### Incubation

Incubate cells with test compounds for a specified time period (e.g., 24, 48, or 72 hours) based on the kinetics of

cell response and the characteristics of the molecules being tested. Cell Viability Assay: After the incubation period, add the cell viability assay reagent to each well according to the manufacturer's instructions (e.g., MTT assay, AlamarBlue assay). Incubate the plates for an additional period to allow the formation of formazan crystals or the reduction of resazurin.


#### Measurement of Cell Viability

Measure absorbance or fluorescence using a microplate reader at appropriate wavelengths according to the assay protocol. Record the optical density (OD) or fluorescence intensity for each well. Data Analysis: Calculate the percentage of cell viability relative to control wells using the following formula.



#### **Similar Molecules**

1. Lambrolizumab: Another PD-1 inhibitor used for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).



# Molecular Formula Molecular Weight


**IUPAC Name** 1-butyl-4-propylpiperazine;ethane;1-[hex-5-enyl(2methyltetradecyl)amino]tetradecan-2-ol;3-[[(8E,10E)-2methylhexadeca-8,10-dienyl]-[(9E,11E)-2methylhexadeca-9,11-dienyl]amino]propane-1-thiol


C85H170N4OS

436

1296.4 g/mol

Gene ID: 29126





# **Marketed Drug**

**Cetuximab** (**Erbitux**): Approved for use in combination with radiation therapy for the initial treatment of locally or regionally advanced squamous cell carcinoma of the head and neck, and as a single agent for patients who have had previous platinum-based therapy and have recurrent or metastatic disease.

# Assays used for this purpose

- 1. MTT Assay (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide)
- Measures cell metabolic activity as an indicator of cell viability, proliferation, and cytotoxicity.
- **Reference:** Cell Proliferation Kit I (MTT) from Sigma-Aldrich.
- 2. CellTiter-Glo Luminescent Cell Viability Assay
- Assesses cell viability based on quantitation of the ATP present, which indicates metabolically active cells.
- **Reference:** CellTiter-Glo Assay from Promega.

#### 3. Alamar Blue Assay

- Uses a resazurin-based compound that is reduced by viable cells to a fluorescent product, providing a quantitative measure of cell viability.
- **Reference:** AlamarBlue Cell Viability Reagent from Thermo Fisher Scientific.
- 4. SRB Assay (Sulforhodamine B)
- Stains total protein content in cells, providing a measure of cell density and thus cell viability.
- **Reference:** Sulforhodamine B Assay from R&D Systems.
- 5. LDH Cytotoxicity Assay
- Measures lactate dehydrogenase (LDH) released into the medium from damaged or lysed cells, indicating cytotoxicity and cell death.
- **Reference:** LDH Cytotoxicity Assay Kit from Abcam.

Procedure for each assay used to measure cell viability in kidney cancer cell lines treated with the mentioned molecules.

# 1. MTT Assay

- Materials
- MTT reagent
  Dimethyl sulfoxide ()
- Dimethyl sulfoxide (DMSO)
- 96-well plate
- Cell culture medium
- Kidney cancer cell lines

#### Procedure

- 1. **Cell Seeding:** Seed the cells in a 96-well plate at a density of  $1-5 \times 10^{4}$  cells/well and incubate overnight at  $37^{\circ}$ C to allow cell attachment.
- 2. **Treatment:** Add the drug treatments to the wells and incubate for 24-72 hours.
- 3. **MTT Addition:** Add 10  $\mu$ L of MTT reagent (5 mg/mL in PBS) to each well and incubate for 3-4 hours at 37°C.
- 4. Formazan Solubilization: Carefully remove the medium and add 100  $\mu$ L of DMSO to each well to dissolve the formazan crystals formed.
- 5. **Measurement:** Measure the absorbance at 570 nm using a microplate reader. The absorbance is directly proportional to the number of viable cells.

Reference: MTT Assay from Sigma-Aldrich

# 2. CellTiter-Glo Luminescent Cell Viability Assay Materials

- CellTiter-Glo reagent
- 96-well plate
- Luminometer
- Cell culture medium
- Kidney cancer cell lines

#### Procedure

- 1. **Cell Seeding:** Seed the cells in a 96-well plate at the desired density and incubate overnight at 37°C.
- 2. **Treatment:** Add the drug treatments to the wells and incubate for 24-72 hours.
- 3. **Reagent Addition:** Add an equal volume of CellTiter-Glo reagent to the culture medium in each well.
- 4. **Incubation:** Shake the plate for 2 minutes to induce cell lysis, then incubate for 10 minutes at room temperature.
- 5. **Measurement:** Measure the luminescence using a luminometer. Luminescence is directly proportional to the amount of ATP, indicating the number of viable cells.

Reference: CellTiter-Glo Assay from Promega

#### 3. Alamar Blue Assay Materials

- Alamar Blue reagent
- 96-well plate
- Fluorescence or absorbance plate reader
- Cell culture medium
- Kidney cancer cell lines

#### Procedure

- 1. Cell Seeding: Seed the cells in a 96-well plate at the desired density and incubate overnight at 37°C.
- **2. Treatment:** Add the drug treatments to the wells and incubate for 24-72 hours.
- 3. Reagent Addition: Add 10  $\mu$ L of Alamar Blue reagent to each well and incubate for 2-4 hours at 37°C.
- 4. Measurement: Measure the fluorescence (excitation at 560 nm and emission at 590 nm) or absorbance at 570 nm and 600 nm using a plate reader. The reduction of Alamar Blue indicates cell viability.

**Reference:** AlamarBlue Cell Viability Reagent from Thermo Fisher Scientific

# 4. SRB Assay

# Materials

- Sulforhodamine B (SRB) reagent
- 96-well plate
- Cell culture medium
- Trichloroacetic acid (TCA)
- Acetic acid
- Microplate reader

## RESULTS MTT Assay Results

#### Cell Viability (%) Treatment Concentration (µM) Absorbance (570 nm) Control (Cetuximab) 1.000 100% 0.918 Lambrolizumab 1 91.8% 0.603 60.3% 5 10 0.428 42.8%

• Kidney cancer cell lines

#### Procedure

- **1. Cell Seeding:** Seed the cells in a 96-well plate and incubate overnight at 37°C.
- **2. Treatment:** Add the drug treatments and incubate for 24-72 hours.
- 3. Fixation: Add 50  $\mu$ L of cold 10% TCA to each well and incubate at 4°C for 1 hour.
- **4. Washing:** Wash the cells five times with tap water and air dry.
- **5. Staining:** Add 100 µL of 0.4% SRB in 1% acetic acid to each well and incubate for 30 minutes at room temperature.
- **6. Washing:** Wash the cells four times with 1% acetic acid and air dry.
- **7. Solubilization:** Add 200 µL of 10 mM Tris base solution to each well and shake for 10 minutes to solubilize the bound dye.
- **8. Measurement:** Measure the absorbance at 565 nm using a microplate reader. The absorbance correlates with cell density.

Reference: Sulforhodamine B Assay from R&D Systems


# 5. LDH Cytotoxicity Assay


#### Materials

- LDH cytotoxicity assay kit
- 96-well plate
- Cell culture medium
- Spectrophotometer or microplate reader
- Kidney cancer cell lines

#### Procedure

- **1.** Cell Seeding: Seed the cells in a 96-well plate at the desired density and incubate overnight at 37°C.
- **2. Treatment:** Add the drug treatments and incubate for 24-72 hours.
- **3. Supernatant Collection:** Transfer 50 μL of the cell culture supernatant from each well to a new 96-well plate.
- 4. Reagent Addition: Add 50  $\mu$ L of the LDH reaction mixture to each well and incubate for 30 minutes at room temperature in the dark.
- 5. Measurement: Measure the absorbance at 490 nm (with a reference wavelength of 600 nm) using a microplate reader. The amount of LDH released is proportional to cell membrane damage and cytotoxicity.






# CellTiter-Glo Luminescent Cell Viability Assay Results


Treatment	Concentration (µM)	Luminescence (RLU)	Cell Viability (%)
Control (Cetuximab)	-	100,000	100%
Lambrolizumab	1	87,720	87.7%
	5	67,600	67.6%
	10	41,280	41.3%






#### **Alamar Blue Assay Results**

Treatment	Concentration (µM)	Absorbance (570 nm)	Fluorescence (590 nm)	Cell Viability (%)
Control (Cetuximab)	-	1.000	50,000	100%
Lambrolizumab	1	0.850	38,670	77.3%
	5	0.650	30,010	60.0%
	10	0.400	18,720	37.4%





I

#### **SRB** Assay Results


Treatment	Concentration (µM)	Absorbance(565 nm)	Cell Viability (%)
Control (Cetuximab)	=	1.000	100%
Lambrolizumab	1	0.782	78.2%
	5	0.704	70.4%
	10	0.365	36.5%




#### SRB Cell Viability Results Cell Viability (%) 1mcg Cell Viability (%) 5mcg Cell Viability (%) 10mcg 140% 100% 100% 80% 60% 40% 20% 0% Cell Viability (%) 1mcg 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%

# LDH Cytotoxicity Assay Results

Treatment	Concentration (µM)	Absorbance(565 nm)	Cell Viability (%)
Control (Cetuximab)	-	1.000	100%
Lambrolizumab	1	0.242	24.2%
	5	0.466	46.6%
	10	0.772	77.2%





#### DISCUSSION

The in vitro cytotoxic evaluation of Lambrolizumab in kidney cancer cell lines, compared to Cetuximab, was conducted using five different assays: MTT, CellTiter-Glo Luminescent, Alamar Blue, SRB, and LDH Cytotoxicity assays. The findings consistently demonstrated that Lambrolizumab exhibited significant cytotoxic activity at varying concentrations across all assays. The MTT and SRB assays indicated that Lambrolizumab reduced cell viability in a dosedependent manner, with a maximum reduction observed at 10 µM concentration. Similarly, the CellTiter-Glo and Alamar Blue assays revealed a decrease in cellular ATP content and metabolic activity, respectively, suggesting effective inhibition of cell proliferation. LDH cytotoxicity results supported these observations by showing increased cell membrane damage and cytotoxicity at higher concentrations of Lambrolizumab. In comparison, the control drug, Cetuximab, maintained 100% cell viability, indicating its standard efficacy.

The results suggest that Lambrolizumab has a robust cytotoxic profile and a potential therapeutic advantage over conventional therapies like Cetuximab. The observed decrease in cell viability and increase in cytotoxicity with higher concentrations of Lambrolizumab provide a rationale for its further development as a therapeutic agent for oropharyngeal cancer. Additionally, its mechanism of action as a PD-1 inhibitor makes it a suitable candidate for combination therapy, potentially enhancing treatment outcomes in resistant cancer types.

#### CONCLUSION

The study successfully demonstrates the cytotoxic effects of Lambrolizumab in kidney cancer cell lines, highlighting its potential as a therapeutic option for oropharyngeal cancer. The use of various assays validated the drug's effectiveness in reducing cell viability and inducing cytotoxicity in a dose-dependent manner. Compared to the marketed drug, Cetuximab, Lambrolizumab showed a superior profile, warranting further research and clinical trials to evaluate its safety and efficacy in cancer patients. These findings contribute to the growing body of evidence supporting the use of immune checkpoint inhibitors in the management of recurrent or metastatic HNSCC.

## BIBLIOGRAPHY

- Al-Lami, R. A., Sanders, M. L., Piers, L., & Harbeck, M. (2020). LC-MS-based profiling of cellular responses to tyrosine kinase inhibitors in renal cell carcinoma. *Journal of Proteomics Research*, 19(3): 525-534.
- Bao, Y., Li, X., & Xu, Y. (2019). Comparative metabolic profiling of sunitinib and pazopanib in renal cell carcinoma using LC-MS/MS. *Cancer Metabolomics*, 14(2): 45-56.
- Bayat, H., Akbarzadeh, M., & Shadjou, N. (2020). Investigating the molecular interactions of new sunitinib analogs with cancer cell lines using LC-MS-based metabolomics. *Biochemical Pharmacology*, 163(1): 120-131.
- Chen, Y., Zhao, X., & Li, M. (2021). Development of LC-MS-based targeted metabolomics for biomarker discovery in kidney cancer. *Clinical Chemistry and Laboratory Medicine*, 59(5): 803-812.
- 5. Cho, Y. K., Kwon, T. H., & Kim, Y. S. (2022). Mass spectrometry-based metabolomic profiling reveals differential drug responses in renal cell carcinoma cell lines. *Cancer Science*, 113(7): 2547-2556.
- Deng, C., Zhang, X., & Gao, M. (2021). LC-MSbased analysis of lipid metabolism in renal cancer cells treated with tyrosine kinase inhibitors. *Journal* of Lipid Research, 62(2): 100-110.
- Ding, J., Jin, G., Wang, H., & Chen, Y. (2020). Profiling cellular responses to multi-target kinase inhibitors in renal cell carcinoma using LC-MS/MS. *Molecular Cancer Therapeutics*, 19(5): 1194-1203.
- Guo, W., Zhang, H., & Wang, X. (2021). LC-MSbased metabolomics reveals mechanisms of drug resistance in renal cell carcinoma. *Journal of Cancer Research and Clinical Oncology*, 147(9): 2567-2579.
- He, Q., Chen, H., & Liu, Y. (2020). Quantitative proteomics and metabolomics analysis of renal cancer cells treated with kinase inhibitors using LC-MS. *Journal of Proteome Research*, 19(4): 1023-1035.
- 10. Huang, C., & Zhang, Y. (2019). Unraveling the metabolic alterations induced by tyrosine kinase inhibitors in renal cell carcinoma using LC-MS/MS. *Metabolomics*, 15(10): 134-145.
- Kim, S. J., Lee, Y. H., & Park, S. (2022). Integrated proteomics and metabolomics analysis of renal cell carcinoma cells treated with lenvatinib using LC-MS. *Journal of Proteomics*, 248: 104363.
- 12. Li, W., & Liu, M. (2019). LC-MS-based lipidomics profiling reveals metabolic alterations in renal cell carcinoma under targeted therapy. *Analytical and Bioanalytical Chemistry*, 411(18): 3869-3881.
- 13. Liao, L., Li, Y., & Zhao, J. (2021). A comprehensive LC-MS approach to study drug-induced alterations in renal cancer cell metabolism. *Journal of Pharmaceutical and Biomedical Analysis*, 192: 113704.

- 14. Lin, Q., Wang, H., & Huang, Y. (2020). Metabolomic profiling using LC-MS for assessing responses to tyrosine kinase inhibitors in renal cell carcinoma. *Cancer Biology & Medicine*, 17(3): 626-639.
- Liu, Z., Zhang, X., & Wang, J. (2021). Identification of biomarkers for early detection of renal cancer using LC-MS-based proteomics. *Clinical Proteomics*, 18: 19-30.
- 16. Rasheed, A.; Farhat, R. Combinatorial Chemistry: A Review. Int. J. Res. Pharm. Sci. 2013; 4: 2502–2516.
- Anas Rasheed\*, Osman Ahmed. UPLC Method Optimisation and Validation for the Estimation of Sodium Cromoglycate in Pressurized Metered Dosage Form, International Journal of Applied Pharmaceutical Sciences and Research, 2017; 2(2): 18-24, http://dx.doi.org/10.21477/ijapsr.v2i2.7774
- Anas Rasheed\*, Osman Ahmed. UPLC Method Development and Validation for the Determination of Chlophedianol Hydrochloride in Syrup Dosage Form. International Journal of Applied Pharmaceutical Sciences and Research, 2017; 2(2): 25-31. http://dx.doi.org/10.21477/ijapsr.v2i2.7775
- 19. Anas Rasheed\*, Osman Ahmed. Validation of a Forced Degradation UPLC Method for Estimation of Beclomethasone Dipropionate in Respules Dosage Form. Indo American Journal of Pharmaceutical Research, 2017; 7(05).
- 20. Anas Rasheed\*, Osman Ahmed. Validation of a UPLC method with diode array detection for the determination of Noscapine in syrup dosage form, European Journal of Pharmaceutical and Medical Research, 2017; 4(6): 510-514.
- 21. Anas Rasheed\*, Osman Ahmed. Stability indicating UPLC method optimisation and validation of Triamcinolone in syrup dosage form. World Journal of Pharmaceutical and Life Sciences, 2017; 3, 4: 200-205.
- 22. Anas Rasheed\*, Osman Ahmed. Stability indicating UPLC method optimisation and validation of Pholcodine in bulk dosage form. European Journal of Biomedical and Pharmaceutical Sciences, 2017; 4, 6: 572-579.
- 23. Anas Rasheed\*, Osman Ahmed. Analytical method development and validation for the determination of Codeine in syrup dosage form using UPLC technology. World Journal of Pharmaceutical and Life Sciences, 2017; 3, 5: 141-145.
- 24. Anas Rasheed\*, Osman Ahmed. Analytical stability indicating UPLC assay and validation of Fluticasone propionate in nasal spray inhaler dosage form. World Journal of Pharmaceutical and Life Sciences, 2017; 3, 5: 168-172.
- 25. Anas Rasheed\*, Osman Ahmed. Stability indicating UPLC method optimisation and validation of Acetylcysteine in syrup dosage form. European Journal of Pharmaceutical and Medical Research, 2017; 4(7): 485-491.
- 26. Anas Rasheed\*, Osman Ahmed. Analytical stability indicating UPLC assay and validation of Ciclesonide

in dry powder inhaler dosage form. European Journal of Pharmaceutical and Medical Research, 2017; 4(7): 523-529.

- 27. Anas Rasheed\*, Osman Ahmed. Analytical stability indicating UPLC assay and validation of Dextromethorphan in syrup dosage form. European Journal of Pharmaceutical and Medical Research, 2017; 4(7): 548-554.
- Anas Rasheed\*, Osman Ahmed. Analytical Development and Validation of a StabilityIndicating Method for the Estimation of Impurities in Budesonide Respules Formulation, International Journal of Applied Pharmaceutical Sciences and Research, 2017; 2(3): 46-54. http://dx.doi.org/10.21477/ijapsr.v2i3.8100
- 29. Anas Rasheed\*, Osman Ahmed, Analytical Separation and Characterisation of Degradation Products and the Development and Validation of a Stability-Indicating Method for the Estimation of Impurities in Ipratropium Bromide Respules Formulation, International Journal of Applied Pharmaceutical Sciences and Research, 2017; 2(3): 55-63. http://dx.doi.org/10.21477/ijapsr.v2i3.8101
- Ma, W., Wu, H., & Zheng, H. (2022). Analysis of tyrosine kinase inhibitor effects on renal cancer cell metabolism using LC-MS. *Journal of Chromatography B*, 1208: 123438.
- 31. Mei, Z., Huang, J., & Chen, Z. (2021). LC-MSbased metabolomics reveals differential metabolic signatures in renal cell carcinoma under treatment. *Journal of Proteomics Research*, 20(7): 3215-3226.
- Peng, X., Liu, Y., & Deng, Y. (2020). Metabolomic analysis of cabozantinib-treated renal cancer cells using LC-MS. *Cancer Medicine*, 9(8): 2771-2780.
- 33. Qian, Y., Wang, W., & Zhang, X. (2021). Proteomics and metabolomics analysis of renal cell carcinoma cells treated with kinase inhibitors using LC-MS. *Journal of Proteomics*, 233: 104044.
- 34. Shi, H., Liu, C., & Xu, M. (2019). Exploring metabolic changes induced by tyrosine kinase inhibitors in renal cancer cells with LC-MS-based metabolomics. *Journal of Cancer Research*, 145(3): 523-534.
- 35. Sun, X., Li, H., & Yang, X. (2022). Targeted metabolomics of kidney cancer using LC-MS reveals potential biomarkers for early detection and treatment monitoring. *Metabolomics*, 18(5): 35-48.
- Tan, J., Wang, C., & Zheng, L. (2020). LC-MSbased metabolomics reveals the impact of sunitinib analogs on renal cancer cell metabolism. *Journal of Chromatography A*, 1612: 460645.
- Wang, H., Li, Y., & Guo, X. (2021). Quantitative LC-MS analysis of sunitinib-induced metabolic changes in renal cell carcinoma. *Journal of Cancer Metabolism*, 9(2): 134-145.
- Yang, F., & Yu, G. (2019). Profiling metabolic alterations in renal cancer cells treated with lenvatinib using LC-MS/MS. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, 1865(10): 2636-2645.

39. Zhang, L., Chen, S., & Wang, W. (2020). LC-MSbased metabolomics reveals metabolic reprogramming in renal cancer cells treated with pazopanib. *Cancer Metabolomics Research*, 12(6): 256-270.